Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population.
Journal: Diabetic medicine : a journal of the British Diabetic Association
Published: October 13, 2025
Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
Journal: Journal of clinical pharmacology
Published: August 13, 2025
Association of Ertugliflozin on Kidney Outcomes in People After and Without an Interval Cardiovascular Event: Observations From the VERTIS CV Trial.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: March 12, 2025
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
Journal: European journal of heart failure
Published: June 27, 2024
Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.
Journal: Diabetes, obesity & metabolism
Published: June 24, 2024
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial.
Journal: Kidney diseases (Basel, Switzerland)
Published: June 18, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.
Journal: Diabetes, obesity & metabolism
Published: May 23, 2024
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
Journal: Diabetes, obesity & metabolism
Published: February 16, 2024
Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts.
Journal: Therapeutic innovation & regulatory science
Published: April 16, 2023
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
Journal: European heart journal
Published: January 22, 2023
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Journal: Diabetes, obesity & metabolism
Published: November 16, 2022
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: October 13, 2022
Last Updated: 09/26/2026